Upload File

Download - Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

Transcript
Page 1: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

Are pharma companies supposed to be private investigators?

Jonathan RichmanDirector of Strategic Planning, Bridge WorldwideAuthor, Dose of Digital

Page 2: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

Required for reporting:

1. an identifiable patient2. an identifiable reporter3. a specific drug or biologic involved in the

event4. an adverse event or fatal outcome

Only 1 in 500 posts have all this info.

Page 3: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

Is this a reportable adverse event?

Page 4: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

1. An Identifiable Patient

Is this “identifiable”?

Page 5: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

1. An Identifiable Patient

Page 6: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

1. An Identifiable Patient

Page 7: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

2. An Identifiable Reporter

Page 8: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

2. An Identifiable Reporter

Page 9: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

3. a specific drug involved in the event

I can't remember the name it was something with a R. I got the shakes so bad that I had to take beta blockers to stop them.

I can't remember the name it was something with a R. I got the shakes so bad that I had to take beta blockers to stop them.

Page 10: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

4. An adverse or fatal outcome

I ‘m beginning to wonder if the Parkinson-like movement of my left hand is related to taking Lipitor

I ‘m beginning to wonder if the Parkinson-like movement of my left hand is related to taking Lipitor

Page 11: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

In the “Old Days”...

Page 12: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

A New Reality1

1. an identifiable patient2. an identifiable reporter3. a specific drug or biologic involved in the event4. an adverse event or fatal outcome

23

4

Page 13: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

A New Reality

HealthGuy

Page 14: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting
Page 15: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

New Guidance Needed?

1. an identifiable patient2. an identifiable reporter3. a specific drug or biologic involved in the

event4. an adverse event or fatal outcome

Page 16: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

New Guidance Needed?

2. an identifiable reporter

Page 17: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

New Guidance Needed?

Page 18: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

New Guidance Needed?

1. an identifiable patient2. an identifiable reporter3. a specific drug or biologic involved in the

event4. an adverse event or fatal outcome

Page 19: Dose of Digital FDA Pharma Social Media Hearing Testimony - Adverse Event Reporting

Jonathan RichmanDirector of Strategic Planning, Bridge WorldwideAuthor, Dose of Digital


Top Related

Adverse Events- Love them, hate them, report them! · 2015. 5. 26. · problems to the FDA. The FDA published a final rule. 2. on Feb. 14, 2014, requiring manufacturers and importers
Adverse Events- Love them, hate them, report them! · 2015. 5. 26. · problems to the FDA. The FDA published a final rule. 2. on Feb. 14, 2014, requiring manufacturers and importers
Evidence - Privilege against Adverse Spousal Testimony - A
Evidence - Privilege against Adverse Spousal Testimony - A
SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) · PMA P100044/S018: FDA Summary of Safety and Effectiveness Data Page 6 Table 1: Adverse Events Occurring in ≥ 2% of Patients* Adverse
SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED) · PMA P100044/S018: FDA Summary of Safety and Effectiveness Data Page 6 Table 1: Adverse Events Occurring in ≥ 2% of Patients* Adverse
New FDA Requirements for Post-Marketing Studies and ... · New FDA Requirements for Post-Marketing ... any information derived from a clinical trial, an adverse event report,
New FDA Requirements for Post-Marketing Studies and ... · New FDA Requirements for Post-Marketing ... any information derived from a clinical trial, an adverse event report,
Dose of Digital FDA Pharma Social Media Hearing Testimony - Corrective Information Strategy
Dose of Digital FDA Pharma Social Media Hearing Testimony - Corrective Information Strategy
Evidence-based Patient Empowerment Smart Healthcare Platformdhsl.ds.unipi.gr/files/C01-IBM-K_KOKKINOS.pdf · reporting adverse drug reaction FDA University of Piraeus 9 Evidence-based
Evidence-based Patient Empowerment Smart Healthcare Platformdhsl.ds.unipi.gr/files/C01-IBM-K_KOKKINOS.pdf · reporting adverse drug reaction FDA University of Piraeus 9 Evidence-based
Molecular Diagnostics Overview - Cancer TreatmentCLIA vs. FDA FDA evaluates medical devices for safety and effectiveness FDA monitors Severe Adverse Events, but not ongoing Quality
Molecular Diagnostics Overview - Cancer TreatmentCLIA vs. FDA FDA evaluates medical devices for safety and effectiveness FDA monitors Severe Adverse Events, but not ongoing Quality
(icosapent ethyl) Retail Fact Sheet for VASCEPA• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088 • Patients receiving VASCEPA and concomitant
(icosapent ethyl) Retail Fact Sheet for VASCEPA• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088 • Patients receiving VASCEPA and concomitant